English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The problem of anti-epileptic drugs (AEDs) insufficient efficiency and risk of clinically significant side effects is still topical. In patients with epilepsy revealed significant individual differences in the therapeutic effect of AEDs from normal and high sensitivity to resistance. There is a need to develop personalized therapeutic strategies that take into account the individual characteristics of the patient. Pharmacogenetic approach is aimed to identify the key genetic biomarkers, and is a powerful tool for the development of personalized medicine. This article discusses the prospective pharmacogenetic markers that influence to the pharmacokinetics of AEDs. Their identification can help to ensure high efficiency and safety of antiepileptic therapy.

BIOLOGICAL MARKERS OF THE ANTIEPILEPTIC DRUGS EFFICACY AND SAFETY: PHARMACOGENETICS AND PHARMACOKINETICS